Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 5/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 2/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20698620 | 0.91 | HIF1A (0.34) | HIF1APTGS2 | |
| SCHEMBL20698887 | 0.88 | HIF1A (0.32) | HIF1APTGS2 | |
| SCHEMBL20698666 | 0.85 | HIF1A (0.48) | HIF1AL3MBTL1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL20698903 | 0.82 | HIF1A (0.33) | HIF1AL3MBTL1SMN1; SMN2TDP1 | |
| SCHEMBL20699051 | 0.82 | HIF1A (0.31) | HIF1APTGS2 | |
| SCHEMBL20698886 | 0.81 | HIF1A (0.30) | HIF1A | |
| SCHEMBL20699003 | 0.79 | HIF1A (0.38) | HIF1APTGS2 | |
| SCHEMBL18292032 | 0.76 | HIF1A (0.39) | HIF1APTGS2 | |
| SCHEMBL20698622 | 0.76 | HIF1A (0.50) | HIF1APTGS2 | |
| SCHEMBL20699002 | 0.76 | HIF1A (0.36) | HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906880-B2 | Kind of isothiazole oxime ether-containing strobilurin derivatives and its preparation methods and application | NANKAI UNIVERSITY (CN) | 2021-02-02 | — | — | US | disclosed |
| US-20190031627-A1 | A KIND OF ISOTHIAZOLE OXIME ETHER-CONTAINING STROBILURIN DERIVATIVES AND ITS PREPARATION METHODS AND APPLICATION | NANKAI UNIVERSITY (CN) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906880-B2 | Kind of isothiazole oxime ether-containing strobilurin derivatives and its preparation methods and application | STS, STAU1, CDV3 | HIF1A 3135/4885L3MBTL1 2684/4885RAB9A 3363/4885 |
| US-20190031627-A1 | A KIND OF ISOTHIAZOLE OXIME ETHER-CONTAINING STROBILURIN DERIVATIVES AND ITS PREPARATION METHODS AND APPLICATION | STS, CDV3, SALL4 | HIF1A 3136/4885L3MBTL1 2750/4885RAB9A 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.